FDA hits Supernus with double whammy, handing biotech a CRL and RTF on same day

Supernus had a bad Monday.

Yesterday, the Maryland biotech announced that two different therapies had been shot back by the FDA. The agency rejected their application to approve SPN-812, an experimental ADHD medication for kids and adolescents. And they refused to even consider an application for SPN-830, a continuous treatment pump meant for Parkinson’s disease.